YED STATES PATENT AND TRADMARK OFFICE In re PATENT APPLICATION of Inventor(s): MATSUI et al. $\gamma_j \mathcal{J}$ Group Art Unit_ Examiner_ A. Marschel Appln No.: <u>07 / 308,28</u>2 NOV series code † † serial no 15 Atty. Dkt. 70177 E-99-89 1990 Filed: February 9, 1989 M# Client Ref. (Our Deposit Account No. 03-3975) / 70177 TYPE a PLATELET-DER 5683 (Our Order No. FACTOR RECEPTOR GENE C# November 15, 1990 Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231 Sir: RESPONSE RESPONSE/AMENDMENT AIRTIER This is a response/xxxxxxxxxxxx in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is to be treated as the signature to the attachment in absence of a signature thereto. FEE REQUIREMENTS FOR CLAIMS AS AMENDED Query: Is appeal deadline now? If Claims Highest so, file Notice of remaining number * Appeal separately * after previously Present AdditIonal amendment paid for Extra x \$20.00 € 1. Total Effective Claims minus 2. Independent Claims minus *** If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time(leave <u>blank</u> if this is a <u>reissue</u> appln)add \$200.00 + Original due date: [] None; [X] (date) August 24, 1990 5. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached (1 month \$100; 2 months \$300; 3 months \$730): - - - - - - - - - -6. If Terminal Disclaimer attached, add Rule 20(d) Official fee (\$100) - -7. Subtotal \$ If "small entity" verified statement filed [] previously, [] herewith, - - - - and <u>subtract</u> enter one-half (1/2) of subtotal - - - - -Subtotal \$_ 10. Enter any previous extension fee paid since above original due date (item 4) and subtract -TOTAL FEE ATTACHED \$ 12. *If the entry in this space is less than entry in the next space, the "Present Extra" result is "O".
13. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.
14.***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space. CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached. This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed KB 11/27/90 07308282 730.00 CK 1615 L Street N.W. CUSHMAN, DARBY & CUSHMAN 26,581 Watson T. Scott Eleventh Floor By Atty:1 Reg. No. Fax: (202) 822-0944 Tel.: (202) 3067 Washington, D.C. 20036-5601 Tel: 861-3000 Atty/Sec: WTS:KIK/tlc

CDC-120 11/90 NOTE: File this cover sheet in <u>duplicate</u> with post card receipt (CDC-103) and attachments

ID MCH TPE NAME OR ACCOUNT C-NBR MLEDTE CURDTE F-C \$ AMOUNT C 100 1 07308282 00060 901115 901127 117 730.00 NO MORE TRANSACTIONS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In respication of

MATSUI et al.

Serial No: 07/308,282

Filed: February 9, 1989

For: TYPE α PLATELET-DERIVED

GROWTH FACTOR RECEPTOR GENE

Examiner: /

Marschela,/A

Group Art Unit: 18

November 5, 1990

RECEIVED

RESTRICTION REQUIREMENT

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In response to the Restriction Requirement of July 24, 1990, applicants' elect Group I drawn to the alpha-PDGF receptor gene and its expression in prosecuting this application. Non-elected claims will be cancelled in due course while reserving the right to file a divisional application covering same.

The Examiner required restriction between the antibodies to PDGF receptor proteins (Group II) and immunoassay

U. S. Application of MATSUI et al. Serial No. 07/308,282 Page 2

methods utilizing these antibodies (Group IV). In future filed divisional applications covering the claim, applicants' make their intention to traverse between the antibodies and antibody immunoassays.

> Respectfully submitted, CUSHMAN, DARBY & CUSHMAN

Watson T. Scott A

Reg. No. 26,581 202-861-3067

WTS:KIK/tlc

1615 L Street, N.W. Suite 1100 Washington, D.C. 20036-5601 Tel: (202) 861-3000